Loading patent…
AssigneeGi Innovation, Inc.
InventorsMyoung Ho JANG, Su Youn NAM, Young Jun KOH, Young-Gyu CHO
Estimating the term…
A pharmaceutical composition containing, as active ingredients, a fusion protein dimer including an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor is disclosed. The fusion protein containing an CD80 fragment, an Fc domain of an immunoglobulin, and an IL-2 variant can activate immune cells such as natural killer cells as well as control the immune cell regulatory activity of regulatory T cells. In addition, the combined administration of the fusion protein and an immune checkpoint inhibitor such as Keytruda known as a PD-1 inhibitor can effectively inhibit cancer. Therefore, a pharmaceutical composition containing, as active ingredients, the fusion protein dimer and an immune checkpoint inhibitor can be effectively applied to the treatment of cancer and has high industrial applicability.
A pharmaceutical composition comprising, as an active ingredient, a fusion protein dimer comprising an IL-2 protein variant comprising substitutions of the 38th and 42nd in the amino acid of SEQ ID NO:
A pharmaceutical composition comprising, as an active ingredient, an immune checkpoint inhibitor selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody and an anti-TIGIT antibody,
A kit comprising:
A pharmaceutical combination comprising, as active ingredients, a fusion protein dimer comprising an IL-2 protein variant comprising substitutions of the 38th and 42nd in the amino acid of SEQ ID NO:
A method for treating cancer, comprising administering to a subject in need thereof, a fusion protein dimer comprising an IL-2 protein variant comprising substitutions of the 38th and 42nd in the amino acid of SEQ ID NO:
A method for treating cancer, comprising administering to a subject in need thereof, an immune checkpoint inhibitor selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody and an anti-TIGIT antibody, as part of a combination therapy comprising the immune checkpoint inhibitor and a fusion protein dimer comprising an IL-2 protein variant comprising substitutions of the 38th and 42nd in the amino acid of SEQ ID NO:
Dependencies are inferred from the claim text.